MedPath

Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients

Completed
Conditions
NSCLC
Interventions
Other: MR and CT imaging
Registration Number
NCT01859650
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Brief Summary

The University of Sheffield is one of the leading centres in the world for basic and translational research with inhaled gas MRI, which provides lung images with unprecedented spatial and temporal resolution. Our previous work demonstrated that inhaled gas MRI can provide significant clinical information for lung cancer radiotherapy planning and post-treatment evaluation. Building upon this unique experience, a multidisciplinary team will conduct an inhaled gas and proton lung MRI study that will address two of the major clinical problems faced by lung cancer patients treated with radiotherapy.

1. Normal lung tissue is often damaged by the curative radiation dose. The investigators hypothesise that regional ventilation-perfusion lung function imaging with inhaled gas and proton MRI before and after treatment will help to lower the risk of radiation-induced lung injury and help to detect such damage at an early stage.

2. Identification of the extent of cancerous tissue is error-prone when planning treatment from CT images alone. The investigators hypothesise that advanced proton MRI techniques will improve the identification of tumour volume, which is critical to successfully targeting the radiation dose.

To achieve these goals, image acquisition and image processing methods will be tested with a study of 20 patients. Results from this study will make an important contribution to improving the treatment of lung disease which is one of the key research priorities of the NHS.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • Patients with an MDT diagnosis of NSCLC based on findings of positive histology, positive PET scan or growth on serial CT scan requiring CT planning for radiotherapy treatment
  • patients aged over 18
  • patients able to undergo MRI scanning.
Exclusion Criteria
  • patients with co-morbid conditions that exclude radiotherapy treatment
  • patients who are pregnant or women with child bearing potential
  • patients unable to give informed consent
  • patients who do not understand English sufficiently to read the patient information sheet, provide informed consent or converse with research staff without interpreters.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
NSCLC patients undergoing RTMR and CT imaging-
Primary Outcome Measures
NameTimeMethod
Percentage of ventilated lung measured using inhaled gas MRIChange between pre treatment (average 10 days before start of treatment) and at 3 months post treatment
Secondary Outcome Measures
NameTimeMethod
Lung tumour volume measured using proton MRIChange between pre-treatment (average 10 days before start of treatment) and at 3 months post treatment
Percentage of ventilated lung measured using CTChange between pre-treatment (average of 10 days before start of treatment) and at 3 months post-treatment

Trial Locations

Locations (1)

Sheffield Teaching Hospitals

🇬🇧

Sheffield, United Kingdom

Sheffield Teaching Hospitals
🇬🇧Sheffield, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath